Clover Biopharmaceuticals, Ltd. (02197.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 1.91

From 52W high−32.64%

Volume3.00M

Market capHKD 2.67B

P/E (TTM)2.7x

P/S (TTM)5389.9x

Div yield—

Key dataSep 18, 2026

Open

HKD 1.91

From 52W high

−32.64%

Volume

3.00M

Market cap

HKD 2.67B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.9x

P/E (TTM)

2.7x

RSI (14)

52.3

MomentumView details →

1D Return

+7.36%

YTD Return

−9.62%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

2.7x

EV/EBITDA

−8.9x

EV/Sales

5147.3x

P/S (TTM)

5389.9x

P/B (TTM)

−2.8x

ProfitabilityView details →

Gross Margin

−9099.11%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−105.27%

ROA (TTM)

348.76%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−99.18%

EPS YoY

+191.67%

FCF YoY

+67.69%

Revenue CAGR 3Y

−70.51%

EPS CAGR 3Y

+77.78%

EBITDA YoY

+72.14%

MomentumView details →

1D Return

+7.36%

YTD Return

−9.62%

1Y Return

+7.36%

RSI (14)

52.3

vs 50D SMA

+4.85%

vs 200D SMA

−6.80%

Capital & dividendView details →

Debt/Equity

−0.00x

Current Ratio

0.73x

Quick Ratio

0.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.86

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

52.20M

Net Income (TTM)

−66.30M

Op. CF (TTM)

−326.23M

Next earningsMar 30, 2027 →

Latest newsMore news →

Clover Biopharmaceuticals announced positive preliminary Phase II clinical trial data for its respiratory combination vaccine candidates SCB-1022 and SCB-1033 in 420 elderly Australians aged 60-85, showing enhanced antibody responses and reduced respiratory infection incidence.13d ago

Clover Biopharmaceuticals reported interim results for the six months ended June 2026, turning a profit of 955 million yuan from a loss of 101 million yuan a year earlier, mainly due to a one-time accounting gain of about 1.087 billion yuan from the GAVI settlement agreement.25d ago

Similar companies

Disc Medicine, Inc.IRON NewAmsterdam Pharma Company N.V.NAMS Nurix Therapeutics, Inc.NRIX Braveheart Bio, Inc.BRVE Immunome, Inc.IMNM Beam Therapeutics Inc.BEAM Find similar companies →

Latest newsMore news →

Clover Biopharmaceuticals announced positive preliminary Phase II clinical trial data for its respiratory combination vaccine candidates SCB-1022 and SCB-1033 in 420 elderly Australians aged 60-85, showing enhanced antibody responses and reduced respiratory infection incidence.13d ago Clover Biopharmaceuticals reported interim results for the six months ended June 2026, turning a profit of 955 million yuan from a loss of 101 million yuan a year earlier, mainly due to a one-time accounting gain of about 1.087 billion yuan from the GAVI settlement agreement.25d ago